20 results
Thumbnail

D1.396 - Drug hypersensitivity reactions in paediatric patients pre and post-liver transplant: a single-center study

Thumbnail

D1.394 - Functional AOC1 variants associated with reduced diamine oxidase activity mimicking multiple drug hypersensitivity and mast cell disorders

Thumbnail

D1.397 - Successfull rapid drug desensitization to cemiplimab in a patient with lung squamous cell carcinoma

Thumbnail

D1.398 - Safety Outcomes and Predictors of Clinically Significant Reactions in Positive Drug Provocation Tests: A 10-Year Tertiary-Center Cohort

Thumbnail

D1.399 - Selective IgE Mediated Anaphylaxis to Gadobutrol and type I Kounis with tolerance to Gadoxetate Disodium

Thumbnail

D1.400 - Omalizumab premedication improves ferric carboxymaltose desensitization outcomes: A Case Report

Thumbnail

D1.401 - Progression from Immediate to Delayed Hypersensitivity: A Rare Case of Iodixanol-Induced Acute Generalised Exanthematous Pustulosis

Thumbnail

D1.402 - Angiotensin-Converting Enzyme Inhibitor–Induced Bradykinin-Mediated Angioedema: Three Cases of Sustained Remission Following Definitive Discontinuation and the Critical Role of the Prescribing Physician

Thumbnail

D3.440 - Long-Term Efficacy and Safety of Donidalorsen for Hereditary Angioedema Among Patients in Europe: A Regional Analysis of the OASISplus Study

Thumbnail

D3.441 - Switching to Donidalorsen for Hereditary Angioedema: 1-Year Results From the Phase 3 OASISplus Study

Thumbnail

D3.444 - Efficacy and Safety of Donidalorsen for Patients With Hereditary Angioedema in Europe Who Switched From Prior Long-Term Prophylaxis: Results From the OASISplus Study

Thumbnail

D3.445 - Validation of a Novel Serum-Based Indirect Basophil Activation Test (iBAT) to Evaluate Efficacy of a Pivotal Phase III PQ Grass Immunotherapy Trial

Thumbnail

D3.437 - Impact of benralizumab on fatigue and health-related quality of life in patients with hypereosinophilic syndrome: findings from the NATRON phase 3 trial

Thumbnail

D3.438 - Clinical outcomes with navenibart according to baseline attack rate, body mass index, and age: results of the ALPHA-STAR trial

Thumbnail

D3.439 - Donidalorsen For The Treatment Of Hereditary Angioedema: 1-Year Results From The OASISplus Open-Label Extension Cohort

Thumbnail

D3.442 - Patient-Reported Outcomes With Long-Term Donidalorsen Treatment Among Patients In Europe With Hereditary Angioedema: 1-Year Interim Results From The OASISplus Open-Label Extension Cohort

Thumbnail

D3.443 - Patient-Reported Outcomes With Long-Term Donidalorsen Treatment Among Patients In Europe With Hereditary Angioedema: 1-Year Interim Results From The OASISplus Switch Cohort

Thumbnail

D3.446 - PROTECT Phase I/IIa Clinical Trial Demonstrated Strong Correlation Between Humoral Immune Response and Dose of VLP Peanut in Healthy Participants

Thumbnail

D3.447 - Pre-clinical Toxicology and Immunogenicity Evidence as a Precursor of the Successful Phase I/IIA Study with VLP Peanut

Thumbnail

D3.448 - Use of Sebetralstat as Short-term Prophylaxis for Patients with Hereditary Angioedema: Results from the KONFIDENT-S Study